Obscuraminol BCAS# 350485-82-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 350485-82-4 | SDF | Download SDF |
PubChem ID | 101101125 | Appearance | Oil |
Formula | C16H31NO | M.Wt | 253.43 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S,3R,7Z)-2-aminohexadeca-7,15-dien-3-ol | ||
SMILES | CC(C(CCCC=CCCCCCCC=C)O)N | ||
Standard InChIKey | WQUFOQOJRNRZNB-JVSIQZEQSA-N | ||
Standard InChI | InChI=1S/C16H31NO/c1-3-4-5-6-7-8-9-10-11-12-13-14-16(18)15(2)17/h3,10-11,15-16,18H,1,4-9,12-14,17H2,2H3/b11-10-/t15-,16+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Structure Identification | Tetrahedron, 2001, 57(21):4579-4588.Obscuraminols, new unsaturated amino alcohols from the tunicate Pseudodistoma obscurum: structure and absolute configuration[Reference: WebLink]
|
Obscuraminol B Dilution Calculator
Obscuraminol B Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.9459 mL | 19.7293 mL | 39.4586 mL | 78.9173 mL | 98.6466 mL |
5 mM | 0.7892 mL | 3.9459 mL | 7.8917 mL | 15.7835 mL | 19.7293 mL |
10 mM | 0.3946 mL | 1.9729 mL | 3.9459 mL | 7.8917 mL | 9.8647 mL |
50 mM | 0.0789 mL | 0.3946 mL | 0.7892 mL | 1.5783 mL | 1.9729 mL |
100 mM | 0.0395 mL | 0.1973 mL | 0.3946 mL | 0.7892 mL | 0.9865 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Obscuraminol F
Catalog No.:BCN1768
CAS No.:350485-01-7
- Obscuraminol E
Catalog No.:BCN1769
CAS No.:350485-00-6
- Obscuraminol D
Catalog No.:BCN1770
CAS No.:350484-99-0
- Obscuraminol C
Catalog No.:BCN1767
CAS No.:350484-95-6
- 2,5-Dihydroxyxanthone
Catalog No.:BCN7573
CAS No.:35040-32-5
- ent-17-Hydroxykaur-15-en-19-oic acid
Catalog No.:BCN4644
CAS No.:35030-38-7
- Brosimacutin G
Catalog No.:BCN3202
CAS No.:350221-50-0
- NHS-Biotin
Catalog No.:BCC3577
CAS No.:35013-72-0
- Cucurbitadienol
Catalog No.:BCN3342
CAS No.:35012-08-9
- 10beta-Hydroxycadina-4,11(13)-dien-12,8beta-olide
Catalog No.:BCN7435
CAS No.:35001-23-1
- 4alpha,6alpha-Dihydroxyeudesm-11(13)-en-12,8beta-olide
Catalog No.:BCN7431
CAS No.:35001-19-5
- Kurarinone
Catalog No.:BCN2985
CAS No.:34981-26-5
- 4-Epi-curcumenol
Catalog No.:BCN3523
CAS No.:350602-21-0
- Isodemethylwedelolacton
Catalog No.:BCN2766
CAS No.:350681-33-3
- Dendocarbin A
Catalog No.:BCN5287
CAS No.:350986-74-2
- H-D-His-OH
Catalog No.:BCC2959
CAS No.:351-50-8
- Adynerin
Catalog No.:BCN4643
CAS No.:35109-93-4
- GNTI dihydrochloride
Catalog No.:BCC7003
CAS No.:351183-88-5
- Blasticidin S HCl
Catalog No.:BCC5565
CAS No.:3513-03-9
- Deacylmetaplexigenin
Catalog No.:BCC8163
CAS No.:3513-04-0
- 5-Nonadecylresorcinol
Catalog No.:BCN7629
CAS No.:35176-46-6
- Isopropylidenylacetyl-marmesin
Catalog No.:BCN6792
CAS No.:35178-20-2
- INCA-6
Catalog No.:BCC2462
CAS No.:3519-82-2
- D-Tetrahydropalmatine
Catalog No.:BCN2334
CAS No.:3520-14-7
Universal vaccine against respiratory syncytial virus A and B subtypes.[Pubmed:28384263]
PLoS One. 2017 Apr 6;12(4):e0175384.
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection in infants, young children, and the elderly. Two subtypes of RSV, A and B, circulate alternately at 1-2-year intervals during epidemics. The attachment glycoprotein (G protein) of RSV is one of the major targets for immune responses. In this study, we generated a recombinant fusion protein, GcfAB, which consists of the central regions (a.a. residues 131-230) of the G proteins of both RSV A (A2 strain) and B (B1 strain) subtypes, and investigated immunogenicity, protective efficacy, and immunopathology. We immunized mice with GcfAB plus cholera toxin as a mucosal adjuvant via intranasal (IN) or sublingual (SL) routes. The IN group showed higher levels of RSV G-specific antibody responses, including serum IgG and mucosal IgA, compared with the SL group. On the contrary, more vigorous RSV G-specific CD4+ T-cell responses were elicited in the SL group than in the IN group after RSV-A but not RSV-B viral challenge. Furthermore, the SL group showed more pulmonary eosinophil recruitment and body weight loss than did the IN group after RSV-A challenge. Both IN and SL immunization with GcfAB provided potential protection against both subtypes of infections. Together, these results suggest that vaccination with GcfAB via an IN route could be a universal vaccine regimen preventing both RSV A and B infections.
Immune Cell Subsets Evaluation as a Predictive Tool for Hepatitis B Infection Outcome and Treatment Responsiveness.[Pubmed:28384114]
Folia Med (Plovdiv). 2017 Mar 1;59(1):53-62.
BACKGROUND: The patient's immune response is one of the major factors influencing HBV eradication or chronification, and it is thought to be responsible for the treatment success. AIM: Our study aimed to investigate whether cellular defense mechanisms are associated with the course of HBV infection (spontaneous recovery [SR] or chronification [CHB]) and with the therapeutic approach. PATIENTS AND METHODS: A total of 139 patients (118 with CHB, 21 SR) and 29 healthy individuals (HI) were immunophenotyped by flowcytometry. Fifty-six patients were treatment-naive, 20 were treated with interferons and 42 with nucleoside/ nucleotide analogues. RESULTS: Deficiency of T lymphocytes, helper-inducer (CD3+CD4+), suppressorcytotoxic (CD8+CD3+) and cytotoxic (CD8+CD11b-, CD8+CD28+) subsets, activated T cells (CD3+HLA-DR+, CD8+CD38+) and increased CD57+CD8- cells, elevated percentages of B lymphocytes and NKT cells were observed in CHB patients compared with HI. In SR patients, elevated CD8+CD11b+, NKT and activated T cells were found in comparison with controls. The higher values of T cells and their subsets in SR patients than in CHB patients reflect a recovery of cellular immunity in resolved HBV infection individuals. In both groups of treated patients, reduced T lymphocytes, CD3+CD4+ and CD8+CD38+ subsets were found in comparison with HI. Higher proportions of cytotoxic subsets were observed in treated patients compared with treatment-naive CHB patients, more pronounced in the group with interferon therapy. CONCLUSION: Our data demonstrate that cellular immune profiles may be of prognostic value in predicting the clinical course of HBV infection, and the determination of the therapeutic response.
Heme oxygenase up-regulation under ultraviolet-B radiation is not epigenetically restricted and involves specific stress-related transcriptions factors.[Pubmed:28384610]
Redox Biol. 2017 Aug;12:549-557.
Heme oxygenase-1 (HO-1) plays a protective role against oxidative stress in plants. The mechanisms regulating its expression, however, remain unclear. Here we studied the methylation state of a GC rich HO-1 promoter region and the expression of several stress-related transcription factors (TFs) in soybean plants subjected to ultraviolet-B (UV-B) radiation. Genomic DNA and total RNA were isolated from leaves of plants irradiated with 7.5 and 15kJm-2 UV-B. A 304bp HO-1 promoter region was amplified by PCR from sodium bisulfite-treated DNA, cloned into pGEMT plasmid vector and evaluated by DNA sequencing. Bisulfite sequencing analysis showed similar HO-1 promoter methylation levels in control and UV-B-treated plants (C: 3.4+/-1.3%; 7.5: 2.6+/-0.5%; 15: 3.1+/-1.1%). Interestingly, HO-1 promoter was strongly unmethylated in control plants. Quantitative RT-PCR analysis of TFs showed that GmMYB177, GmMYBJ6, GmWRKY21, GmNAC11, GmNAC20 and GmGT2A but not GmWRK13 and GmDREB were induced by UV-B radiation. The expression of several TFs was also enhanced by hemin, a potent and specific HO inducer, inferring that they may mediate HO-1 up-regulation. These results suggest that soybean HO-1 gene expression is not epigenetically regulated. Moreover, the low level of HO-1 promoter methylation suggests that this antioxidant enzyme can rapidly respond to environmental stress. Finally, this study has identified some stress-related TFs involved in HO-1 up-regulation under UV-B radiation.